Lamotrigine for OCD: Augmentation Strategy Only
Lamotrigine should not be used as monotherapy for OCD, but may be considered as an augmentation agent to SSRIs in treatment-resistant cases, though it is not a first-line augmentation option.
Treatment Algorithm for OCD
First-Line Treatment
- SSRIs are the established first-line pharmacological treatment 1
- CBT with exposure and response prevention (ERP) is equally effective
- SSRI trials should last 8-12 weeks at adequate doses (often higher than used for depression) 1
When First-Line Treatment Fails
Approximately 50% of patients fail to respond adequately to initial SSRI therapy 1. The evidence-based augmentation hierarchy is:
Tier 1 Augmentation (Strongest Evidence):
- N-acetylcysteine: Largest evidence base (3 of 5 RCTs positive) 1
- Memantine: Multiple trials demonstrate efficacy; can be considered in clinical practice 1
- Antipsychotics (risperidone, aripiprazole): Most commonly used strategy, though only 1/3 of SSRI-resistant patients show meaningful response 1
Tier 2 Augmentation (Moderate Evidence):
- Lamotrigine: Grouped among glutamatergic agents with "some evidence of efficacy" 1
Lamotrigine-Specific Evidence
Supporting Data
The 2023 network meta-analysis found lamotrigine produced a 6-point reduction in Y-BOCS scores (MD: -6; 95% CrI: -12, -0.47) with moderate certainty of evidence 2. This ranks it behind memantine but ahead of many other agents.
Two double-blind RCTs support efficacy:
- 2016 Iranian trial: 100mg lamotrigine showed significant improvement in Y-BOCS obsessions (p=0.01), compulsions (p=0.005), and total scores (p=0.007) at 12 weeks 3
- 2012 trial: 100mg lamotrigine over 16 weeks significantly improved obsessions, compulsions, and total Y-BOCS (all p<0.0001) 4
Critical Caveats
Lamotrigine can paradoxically induce OCD symptoms. A 2019 case series documented 8 patients with bipolar disorder who developed de novo obsessions and compulsions 2-8 months after starting lamotrigine, meeting DSM-5 criteria for medication-induced OCD. Symptoms resolved within one month of discontinuation in most cases 5.
This creates a clinical dilemma: the same medication that may help treatment-resistant OCD can also trigger obsessive-compulsive symptoms in susceptible individuals.
Clinical Positioning
Lamotrigine is a third-line option for SSRI augmentation in treatment-resistant OCD, after:
- Optimizing SSRI dose/duration
- Trying N-acetylcysteine or memantine
- Considering antipsychotic augmentation (if appropriate for risk-benefit profile)
Dosing When Used
- Start at 25mg and titrate slowly per standard lamotrigine protocols (to minimize rash risk)
- Target dose: 100mg daily based on trial evidence 3, 4
- Duration: Assess response at 8-12 weeks
Monitoring Requirements
- Watch for emergence or worsening of obsessive-compulsive symptoms, particularly in first 2-8 months 5
- Monitor for serious dermatologic reactions (Stevens-Johnson syndrome risk)
- Assess metabolic parameters (lamotrigine has better metabolic profile than antipsychotics)
When to Consider Lamotrigine
Lamotrigine augmentation may be particularly appropriate when:
- Patient has failed N-acetylcysteine and/or memantine augmentation
- Antipsychotic augmentation is contraindicated or poorly tolerated (metabolic concerns)
- Comorbid bipolar depression exists (lamotrigine's primary indication) 6
- Patient cannot tolerate clomipramine augmentation risks (seizures, arrhythmia, serotonin syndrome) 1
The evidence supports lamotrigine as a reasonable option in the glutamatergic augmentation category, but it should not be positioned ahead of agents with stronger evidence bases 1, 2.